About Next-Gen Sequencing

The first-generation Sanger sequencing method has inherent technical limitations including low-throughput, slow speed, high cost, and difficulty to analyze allele frequency. To achieve the goal of $1,000 human genome, new sequencing technologies have been coming out since 2004. These technologies are massively parallel, thereby achieving high-throughput. The streamlined sample prep step prior to sequencing leads to significant savings in time and cost. Since each sequencing reaction is carried out on one piece of DNA, different alleles can be analyzed at the same time.


Key steps of the sequencing-by-synthesis-based Illumina sequencing procedure

CMADP Events

Special seminar by Dr. Kevin W. Plaxco
Professor of Chemistry & Biochemistry
UC Santa Barbara

Wednesday, April 19, 2017 at 4:00pm
School of Pharmacy, Room 3020

"Counting molecules, dodging blood cells: real-time molecular measurements directly in the living body"
The development of technology capable of continuously tracking the levels of drugs, metabolites, and biomarkers in situ in the body would revolutionize our understanding of health and our ability to detect and treat disease. It would, for example, provide clinicians with a real-time window into organ function and would enable therapies guided by patient-specific, real-time pharmacokinetics, opening a new dimension in personalized medicine. In response my group has pioneered the development of a “biology-inspired” electrochemical approach to monitoring specific molecules that supports real-time measurements of arbitrary molecular targets (irrespective of their chemical reactivity) directly in awake, fully ambulatory subjects.
KU Today